[go: up one dir, main page]

NO20002998L - Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet - Google Patents

Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet

Info

Publication number
NO20002998L
NO20002998L NO20002998A NO20002998A NO20002998L NO 20002998 L NO20002998 L NO 20002998L NO 20002998 A NO20002998 A NO 20002998A NO 20002998 A NO20002998 A NO 20002998A NO 20002998 L NO20002998 L NO 20002998L
Authority
NO
Norway
Prior art keywords
alkyl
optionally substituted
cycloalkylalkyl
cycloalkenyl
cycloalkyl
Prior art date
Application number
NO20002998A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002998D0 (no
Inventor
David J Cavalla
Mark Chasin
Peter Hofer
Andre Gehrig
Peter Wintergerst
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20002998D0 publication Critical patent/NO20002998D0/no
Publication of NO20002998L publication Critical patent/NO20002998L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO20002998A 1997-12-12 2000-06-09 Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet NO20002998L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6937197P 1997-12-12 1997-12-12
PCT/US1998/026293 WO1999031102A1 (fr) 1997-12-12 1998-12-11 Derives de purine presentant une activite inhibitrice contre la phosphodiesterase iv

Publications (2)

Publication Number Publication Date
NO20002998D0 NO20002998D0 (no) 2000-06-09
NO20002998L true NO20002998L (no) 2000-07-19

Family

ID=22088545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002998A NO20002998L (no) 1997-12-12 2000-06-09 Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet

Country Status (19)

Country Link
US (5) US6040447A (fr)
EP (3) EP1044201A4 (fr)
JP (5) JP2002508378A (fr)
KR (3) KR100349385B1 (fr)
CN (3) CN1294590A (fr)
AT (1) ATE244243T1 (fr)
AU (5) AU1723099A (fr)
BR (3) BR9815170A (fr)
CA (3) CA2313004A1 (fr)
DE (3) DE19882892T1 (fr)
DK (1) DK1045849T3 (fr)
ES (1) ES2202924T3 (fr)
GB (2) GB2346879B (fr)
HU (3) HUP0301166A2 (fr)
NO (1) NO20002998L (fr)
PL (1) PL341108A1 (fr)
PT (1) PT1045849E (fr)
TR (1) TR200001706T2 (fr)
WO (5) WO1999031103A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367143A1 (fr) * 1999-04-02 2000-10-12 Euro-Celtique S.A. Derives de purine possedant une activite d'inhibition de la phosphodiesterase iv
ATE279113T1 (de) * 1999-08-12 2004-10-15 Euro Celtique Sa Hypoxanthin- und thiohypxanthin-verbindungen
AU2002313673B2 (en) * 2001-02-08 2006-09-07 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7335654B2 (en) * 2002-08-08 2008-02-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
JP2005538134A (ja) * 2002-08-08 2005-12-15 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４阻害剤
US20040063938A1 (en) * 2002-09-30 2004-04-01 Pfizer Inc Process for preparing haloalkyl pyrimidines
BRPI0412502A (pt) * 2003-07-10 2006-09-19 Achillion Pharmaceuticals Inc derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
US20080280926A1 (en) * 2003-12-16 2008-11-13 Palle Venkata P Phosphodiesterase Inhibitors
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
DE102006033572A1 (de) 2006-07-20 2008-01-24 Bayer Cropscience Ag N'-Cyano-N-halogenalkyl-imidamid Derivate
WO2008030651A1 (fr) 2006-09-08 2008-03-13 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101952455A (zh) 2007-12-17 2011-01-19 卢克斯创新有限公司 用于维护流体输导和容纳系统的组合物和方法
EA018907B1 (ru) * 2009-01-30 2013-11-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Кристаллический гидрохлорид n-{(1s)-2-амино-1-[(3-фторфенил)метил]этил}-5-хлор-4-(4-хлор-1-метил-1h-пиразол-5-ил)-2-тиофенкарбоксамида
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
CA3142817A1 (fr) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Composes benzaldehyde substitues et procedes d'utilisation de ceux-ci dans l'augmentation de l'oxygenation des tissus
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2014150258A1 (fr) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Composés et ses utilisations pour la modulation de l'hémoglobine
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA037091B1 (ru) 2013-03-15 2021-02-04 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
KR102345380B1 (ko) 2014-02-07 2021-12-29 글로벌 블러드 테라퓨틱스, 인크. 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
SI3383392T1 (sl) 2015-12-04 2025-10-30 Global Blood Therapeutics, Inc. Režimi odmerjanja za 2-hidroksi-6-((2-(1-izopropil-1h-pirazol-5-il)piridin-3-il)metoksi)benzaldehid
WO2017123766A1 (fr) * 2016-01-12 2017-07-20 Sperovie Biosciences, Inc. Composés et compositions pour le traitement d'une maladie
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2020072377A1 (fr) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose
RU2746012C2 (ru) * 2019-05-13 2021-04-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844577A (en) * 1958-07-22 Certificate of correction
US2956998A (en) 1960-10-18 Adenine derivatives and process
US3215696A (en) * 1965-11-02 Substituted adenines -and preparation thereof
US2903455A (en) 1959-09-08 Jdnviiiiaisnvhi jo
US2697709A (en) 1951-06-14 1954-12-21 Burroughs Wellcome Co Mercapto heterocycles and method of making
US2691654A (en) * 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US2966488A (en) * 1956-07-30 1960-12-27 Shive William Substituted alkylaminopurines
US2957875A (en) 1957-11-18 1960-10-25 Upjohn Co Derivatives of purine
US3079378A (en) 1960-02-01 1963-02-26 Upjohn Co Acylated psicofuranosyladenines
BE601946A (fr) * 1960-03-31
US3135753A (en) 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
FR1548252A (fr) 1961-10-13 1968-12-06
IL24679A (en) * 1965-11-24 1971-10-20 Yissum Res Dev Co Derivatives of 3-methyl purine and methods of preparing the same
US3669979A (en) 1967-12-14 1972-06-13 Gaf Corp Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst
US3952001A (en) 1970-07-01 1976-04-20 The Boots Company Limited 1-Carbamoyl-1,2,4-triazoles
JPS5121529A (ja) 1974-08-16 1976-02-20 Hitachi Ltd Pirorinsandometsukizeiseihimakuboshiho
USRE31429E (en) 1977-02-14 1983-10-25 Merck & Co., Inc. Process for preparation of 9-(dihalobenzyl)adenines
GB2041359B (en) 1979-01-10 1982-12-15 Ici Ltd Purine derivatives and their use in the defoliation of cotton plants
US4241063A (en) 1979-08-06 1980-12-23 Bristol-Myers Company Purine derivatives and their use as bronchodilators
US4361699A (en) 1981-09-28 1982-11-30 Merck & Co., Inc. Novel process for the preparation of N6 -alkyl-arprinocid
US4407802A (en) 1981-09-28 1983-10-04 Merck & Co., Inc. 6-Amidino-9-substituted benzyl purines
GB2120065B (en) 1982-04-27 1986-01-02 Michael Frederick Huber Heating plants
US4492592A (en) 1983-06-06 1985-01-08 Shell Oil Company Combined desiccation of substantially supercritical CO2
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US4883801A (en) 1984-09-07 1989-11-28 The General Hospital Corporation Xanthine derivative pest control agents
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
FI875724A7 (fi) 1986-04-29 1987-12-28 Pfizer Kalsiumista riippumaton cAMP fosfodiesteraasi-inhibiittori-masennukse nvastainen lääke.
GB8618931D0 (en) 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US5057517A (en) 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
US5091431A (en) 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
EP0363320A3 (fr) 1988-10-06 1991-11-21 Ciba-Geigy Ag 9H-purine substituée
US4971972A (en) 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
CA2028235C (fr) 1989-10-20 1997-01-21 Fumio Suzuki Derives puriques condenses
US5117830A (en) 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
JP3264492B2 (ja) 1992-01-13 2002-03-11 スミスクライン・ビーチャム・コーポレイション ピリジル置換イミダゾール
DK0607373T3 (da) 1992-06-15 1997-10-13 Celltech Therapeutics Ltd Trisubstituerede phenylderivater som selektive phosphodiesterase IV-inhibitorer.
DE69333688T2 (de) 1992-07-28 2005-11-03 Aventis Pharma Ltd., West Malling Inhibitoren von c-amp phosphodiesterase
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
DE69332762T2 (de) 1992-12-02 2003-08-14 Pfizer Inc., New York Cathecoldiether als selektive pde iv hemmungsmittel
TW263495B (fr) 1992-12-23 1995-11-21 Celltech Ltd
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Also Published As

Publication number Publication date
HUP0100305A2 (hu) 2002-01-28
CA2314335A1 (fr) 1999-06-24
JP2002508376A (ja) 2002-03-19
WO1999031102A1 (fr) 1999-06-24
EP1045849B1 (fr) 2003-07-02
JP2002508377A (ja) 2002-03-19
GB2346879A (en) 2000-08-23
US6057445A (en) 2000-05-02
AU747366B2 (en) 2002-05-16
KR100349385B1 (ko) 2002-08-24
KR20010032681A (ko) 2001-04-25
GB0013780D0 (en) 2000-07-26
US6228859B1 (en) 2001-05-08
DE69816127D1 (de) 2003-08-07
AU1723099A (en) 1999-07-05
AU1722999A (en) 1999-07-05
PL341108A1 (en) 2001-03-26
CA2313004A1 (fr) 1999-06-24
BR9815171A (pt) 2000-10-10
WO1999031103A1 (fr) 1999-06-24
AU1722899A (en) 1999-07-05
JP3504234B2 (ja) 2004-03-08
PT1045849E (pt) 2003-11-28
WO1999029694A1 (fr) 1999-06-17
DE19882893T1 (de) 2001-02-22
GB0013781D0 (en) 2000-07-26
DE19882892T1 (de) 2001-02-22
EP1045850A1 (fr) 2000-10-25
KR20010033049A (ko) 2001-04-25
ATE244243T1 (de) 2003-07-15
GB2346878A (en) 2000-08-23
DE69816127T2 (de) 2004-04-22
BR9815170A (pt) 2000-10-10
NO20002998D0 (no) 2000-06-09
HUP0100417A2 (hu) 2001-12-28
EP1045849A4 (fr) 2001-10-31
TR200001706T2 (tr) 2000-11-21
GB2346879B (en) 2002-12-04
KR20010032979A (ko) 2001-04-25
US6211367B1 (en) 2001-04-03
BR9815169A (pt) 2000-10-10
WO1999031105A1 (fr) 1999-06-24
AU1820899A (en) 1999-06-28
HUP0301166A2 (en) 2003-08-28
CN1294590A (zh) 2001-05-09
CN1284077A (zh) 2001-02-14
EP1045850A4 (fr) 2001-10-31
CA2313150A1 (fr) 1999-06-17
JP2002508378A (ja) 2002-03-19
AU1815999A (en) 1999-07-05
US6040447A (en) 2000-03-21
JP2002508379A (ja) 2002-03-19
EP1044201A4 (fr) 2001-10-31
EP1045849A1 (fr) 2000-10-25
US6037470A (en) 2000-03-14
JP2001525412A (ja) 2001-12-11
ES2202924T3 (es) 2004-04-01
WO1999031104A1 (fr) 1999-06-24
DK1045849T3 (da) 2003-10-27
CN1281458A (zh) 2001-01-24
GB2346878B (en) 2002-12-04
HUP0100417A3 (en) 2002-04-29
EP1044201A1 (fr) 2000-10-18

Similar Documents

Publication Publication Date Title
NO20002998L (no) Purinderivater som har fosfodiesterase IV inhibisjonsaktivitet
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
CA2382919A1 (fr) Derives d'imidazo-3-yl-amine bicycliques
DK1401837T3 (da) Purinderivater som A2B-adenosinreceptorantagonister
CA2116782A1 (fr) 1h-imidazo¬4,5-c|quinolin-4-amines substituees en position 1; intermediaire et compositions pharmaceutiques
CA2387533A1 (fr) Derives de la purine
CA2387531A1 (fr) Derives de purine
CA2379786A1 (fr) Derives de purine
CA2194984A1 (fr) Derives 4-indole utilises comme agonistes et antagonistes de la serotonine
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
CA2297825A1 (fr) Derives indole et 2,3-dihydro-indole, leur preparation et utilisation
CA2308192A1 (fr) Composes nucleosides de 4'-c-ethynyl pyrimidine
NO20040881L (no) Orale antidiabetes midler.
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
CA2238875A1 (fr) Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv
HK1046405A1 (zh) 作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物
WO2000068198A3 (fr) Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
MXPA04009162A (es) Derivados de piperidina u 8-aza-biciclo[3.2.1]oct-3-ilo empleados como moduladores de actividad del receptor de quimiocina (especialmente ccr5).
WO2003008365A3 (fr) Derives de phenylacetamido-thiazole, leur procede de preparation et leur utilisation en tant qu'agents antitumoraux
WO2000059449A3 (fr) Derives de purine possedant une activite d'inhibition de la phosphodiesterase iv
NO20062491L (no) Benzoksazinderivter og deres anvendelse
BR0211938A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do dito composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo, e, método para tratar os distúrbios de fertilidade em pacientes em necessidade do mesmo
WO2003082881A3 (fr) Derives du pyridoxal-5-phosphate en tant qu'inhibiteurs de l'integrase du vih
AU2001278708A1 (en) Adenosine derivatives and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application